Athenex announced the launch of Levothyroxine Sodium for injection through its subsidiary Athenex Pharmaceutical Division, or APD. The APD product was brought to market in close cooperation with development partner, MAIA Pharmaceuticals. APD is focused on supplying the U.S. hospital market with specialty injectable products that address unmet or underserved hospital needs, including high-volume, niche and/or shortage products. The Levothyroxine Sodium for injection market in the United States exceeds $85M annually.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.